Cybin Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYBN American 8731 https://www.cybin.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cybin Inc

Cybin Announces Date of Annual and Special Meeting of Shareholders - Sep 21st, 2023 9:00 pm
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder - Sep 21st, 2023 11:30 am
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines - Sep 5th, 2023 11:30 am
Cybin to Acquire Small Pharma Inc. - Aug 28th, 2023 5:23 pm
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million - Aug 24th, 2023 1:37 am
Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs - Aug 21st, 2023 5:40 pm
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial - Aug 17th, 2023 11:30 am
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program - Aug 15th, 2023 11:52 am
Cybin Reports First Quarter Financial Results and Recent Business Highlights - Aug 14th, 2023 11:30 am
Cybin Announces Closing of Overnight Marketed Public Offering of Units - Aug 4th, 2023 1:46 pm
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder - Aug 2nd, 2023 11:30 am
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units - Aug 1st, 2023 1:32 pm
Cybin Announces Overnight Marketed Public Offering of Units - Jul 31st, 2023 10:29 pm
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference - Jul 27th, 2023 11:30 am
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder - Jul 26th, 2023 11:30 am
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder - Jul 24th, 2023 11:55 am
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain - Jul 20th, 2023 9:01 pm
Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects - Jul 20th, 2023 12:00 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Jul 17th, 2023 12:44 pm
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT - Jul 12th, 2023 11:30 am